Related Experiment Video
Updated: Jun 22, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential
Chee-Wai Chua1, Yung-Tuen Chiu, Hiu-Fung Yuen
1Cancer Biology Group, Department of Anatomy and Departments of Pathology and Surgery, Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Purpose:
Previously, FTY720 was found to possess potent anticancer effects on various types of cancer. In the present study, we aimed to first verify the role of Runx2 in prostate cancer progression and metastasis, and, subsequently, assessed if FTY720 could modulate Runx2 expression, thus interfering downstream events regulated by this protein.
Experimental Design:
First, the association between Runx2 and prostate cancer progression was assessed using localized prostate cancer specimens and mechanistic investigation of Runx2-induced cancer aggressiveness was then carried out. Subsequently, the effect of FTY720 on Runx2 expression and transcriptional activity was investigated using PC-3 cells, which highly expressed Runx2 protein. Last, the involvement of Runx2 in FTY720-induced anticancer effects was evaluated by modulating Runx2 expression in various prostate cancer cell lines.
Results:
Runx2 nuclear expression was found to be up-regulated in prostate cancer and its expression could be used as a predictor of metastasis in prostate cancer. Further mechanistic studies indicated that Runx2 accelerated prostate cancer aggressiveness through promotion of cadherin switching, invasion toward collagen I, and Akt activation. Subsequently, we found that FTY720 treatment down-regulated Runx2 expression and its transcriptional activity, as well as inhibited its regulated downstream events. More importantly, silencing Runx2 in PC-3 enhanced FTY720-induced anticancer effects as well as cell viability inhibition, whereas overexpressing Runx2 in 22Rv1 that expressed very low endogenous Runx2 protein conferred resistance in the same events.
Conclusion:
This study provided a novel mechanism for the anticancer effect of FTY720 on advanced prostate cancer, thus highlighting the therapeutic potential of this drug in treating this disease.
Insights
FTY720 effectively inhibits prostate cancer progression by down-regulating Runx2 expression. This study reveals a novel mechanism for FTY720
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- FTY720 demonstrates significant anticancer properties across various cancer types.
- Runx2 is implicated in the progression and metastasis of prostate cancer.
Purpose of the Study:
- To investigate the role of Runx2 in prostate cancer progression and metastasis.
- To determine if FTY720 can modulate Runx2 expression and its downstream effects.
Main Methods:
- Assessed Runx2 association with prostate cancer progression using patient specimens.
- Investigated FTY720's effect on Runx2 expression and activity in PC-3 cells.
- Evaluated Runx2's involvement in FTY720's anticancer effects by modulating its expression.
Main Results:
- Runx2 nuclear expression is elevated in prostate cancer and predicts metastasis.
- Runx2 promotes prostate cancer aggressiveness via cadherin switching, collagen I invasion, and Akt activation.
- FTY720 down-regulates Runx2, inhibiting its downstream pathways; Runx2 silencing enhances FTY720 effects, while overexpression confers resistance.
Conclusions:
- FTY720 exhibits anticancer effects in advanced prostate cancer by targeting Runx2.
- This study elucidates a novel mechanism for FTY720's therapeutic action.
- Highlights FTY720's potential as a treatment for prostate cancer.
More Related Videos
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018